The overarching objective of GEODE is to advance our understanding of the complex mechanisms driving the development and progression of gastroesophageal (pre)neoplasia and motility disorders, and better define the roles of host genetic, non-genetic, and microbial factors. 

To accomplish this objective, GEODE will leverage innovative predictive modeling techniques, biospecimens obtained from the IRB approved Foregut Biorepository, and clinical trial and epidemiologic methods. 

GEODE was co-founded and is co-directed by Rena Yadlapati, MD MSHSOR (GEODE Director of Clinical Trials and Outcomes) Kathleen (Kit) Curtius, PhD (GEODE Director of Computational Biology), and Shailja Shah, MD MPH (GEODE Director of Epidemiology and Genomics). Please contact Dr. Yadlapati, Dr. Curtius, or Dr. Shah if interested in enrolling patients, or learning more about this exciting new research initiative.